TABLE 1.
Clinical characteristics of patients with intractable TLE and control patients.
| Number | Sex (M/F) | Age (Years) | Course (Years) | AEDs taken before surgery |
| T1 | F | 26 | 7 | CBZ, VPA, OXC, TPM |
| T2 | M | 22 | 5 | CBZ, TPM, CZP |
| T3 | F | 25 | 10 | CBZ, PB, LTG, LEV |
| T4 | M | 24 | 8 | VPA, CBZ, TPM, PB |
| T5 | M | 18 | 7 | PHT, PB, CBZ, VPA |
| T6 | F | 35 | 10 | CBZ, VPA, TPM, OCX |
| T7 | F | 22 | 9 | CBZ, TPM, CZP |
| T8 | M | 29 | 14 | CBZ, LTG, LEV, PB |
| C1 | M | 11 | 0 | None |
| C2 | F | 38 | 0 | None |
| C3 | M | 40 | 0 | None |
| C4 | F | 34 | 0 | None |
| C5 | M | 30 | 0 | None |
| C6 | F | 17 | 0 | None |
| C7 | M | 11 | 0 | None |
| C8 | M | 25 | 0 | None |
T, TLE temporal lobe epilepsy; C, control; M, male; F, female; CBZ, carbamazepine; LTG, lamotrigine; LEV, levetiracetam; OXC, oxcarbazepine; PHT, phenytoin; PB, phenobarbital; TPM, topiramate; VPA, valproic acid.